Anderson, B.A. et al., “Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164,” J. Am. Chem. Soc. 117: 12358-12359 (1995). |
Buchan, A.M. et al., “Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia,” Neuroreport 2:473-476 (1991). |
Buchan, A.M. et al., “AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?” Stroke Suppl. I 24:I-148-I-154 (1993). |
Choi, D.W. et al., “Glutamate Neurotoxicity in Cortical Cell Culture,” J. Neurosci 7:357-368 (1987). |
Coombs, R.V., et al., “Synthesis and Antiinflammatory Activity of 1-Alkyl-4-aryl-2(1H)-quinazolinones and Quinazolinethiones,” J. Med. Chem. 16:1237-1245 (1973). |
Copani, A. et al., “Nootropic Drugs Positively Modulate α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid-Sensitive Glutamate Receptors in Neuronal Cultures,” J. Neurochem. 58: 1199-1204 (1992). |
De Sarro, G. et al., “GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice,” Eur. J. Pharmacol. 294:411-422 (1995). |
Fetter, J. et al., “Electron Deficient Heteroaromatic Ammonioamidates-XVI,” Tetrahedron 34:2557-2563 (1978). |
Graham, S.H. et al., “A Dose-Response Study of Neuroprotection using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia,” J. Pharm. Exp. Ther. 276: 1-4 (1996). |
Haider, N., “Convenient Synthesis of Cycloalkene-Fused Phthalazinones,” Heterocycles 41: 2519-2525 (1995). |
Houlihan, W.J. et al., “Antiinflammatory Properties of 8-Aryl-5-isopropyl-2H-1,3-dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones,” J. Med. Chem. 25:1110-1113 (1982). |
Hunter, J.C. and L. Singh, “Role of exitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat,” Neurosci Lett. 174:217-221 (1994). |
Ikeda, A. et al., “Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan,” Movement Disorders 11:691-700 (1996). |
Iwasaki, Y. et al., “CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats,” J. Neurosci. 134 21-25 (1995). |
Jones, B. et al., “The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist,” Br. J. Pharmacol. 93:985-993 (1988). |
Keana, J.F.W. et al., “Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2-3-diones: Antagonists of N-Methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Gluatamate Receptors,” J. Med. Chem. 38:4367-4379 (1995). |
Larson, J. et al., “Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats,” Brain Res. 738:353-356 (1996). |
Le Peillet, E. et al., “The non-NMDA antagonists, NBQX and GYKI 52466, protect against coritcal and striatal cell loss following transient global ischaemia in rat,” Brain Res. 571:115-120. |
Lipton, S. and P.A. Rosenberg, “Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders,” N. Engl. J. Med. 330:613-622 (1994). |
McDonald,, J.W. et al., “Physiological and pathophysiological roles of excitatory amino acids during central nervous system development,” Brain Res. Rev. 15:41-70 (1990). |
Pelletier, J.C. et al., “Substituted 1,2-Dihydrophthalazines: Potent, Selective, and Noncompetive Inhibitors of the AMPA Receptor,” J. Med. Chem. 39:343-346 (1996). |
Sang, C.N. et al., “Analgesic Effects of AMPA/Kainate Antagonist LY293558 in Human: Reduction of Capsaicin-Evoked Allodynia and Hyperalgesia But Not Pain Sensations in Normal Skin,” Soc. Neuroci 23:1015, Abstract No. 401.14 (Oct. 1997). |
Schoepp, D. et al., “Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors,” Trends Pharm Sci 11:508-515 (1990). |
Sheardown, M.J. et al., “2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxalin: A Neuroprotectant for Cerebral Ischemia,” Science 247:571-574 (1990). |
Sheardown, M.J. et al., “AMPA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h,” Eur. J. Pharmacol. 236:347-353 (1993). |
Staubli, U. et al., “Facilitation of glutamate receptors enhances memory,” Proc. Natl. Acad. Sci. USA 91:777-781 (1994). |
Thomas, R.J., “Excitatory Amino Acids in Health and Disease,” J. Am. Geriatr. Soc. 43:1279-1289 (1995). |
Woodward, R.M. et al., “In Vitro Pharmacology of ACEA-1021 and ACEA 1031: Systemically Active Quinoxalinediones with High Affinity and Selectivity for N-Methyl-D-aspartate Receptor Glycine Sites,” Mol. Pharmacol. 47:568-581 (1995). |
Wrathall, J.R. et al., “Amelioration on Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-Methyl-D-Aspartate receptors,” Exp. Neurology 137:119-126 (1996). |
Dialog File 351, Accession No. 1973-41080U/197329, Derwent WPI English language abstract for DE 2307808. |